These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 16177277)

  • 1. Predicting drug efficacy for cognitive deficits in schizophrenia.
    Hagan JJ; Jones DN
    Schizophr Bull; 2005 Oct; 31(4):830-53. PubMed ID: 16177277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia.
    Floresco SB; Geyer MA; Gold LH; Grace AA
    Schizophr Bull; 2005 Oct; 31(4):888-94. PubMed ID: 16079387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of cognitive dysfunction in schizophrenia.
    Peuskens J; Demily C; Thibaut F
    Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia.
    AhnAllen CG
    Curr Opin Psychiatry; 2012 Mar; 25(2):103-8. PubMed ID: 22262029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target.
    Barak S; Weiner I
    Pharmacol Biochem Behav; 2011 Aug; 99(2):164-89. PubMed ID: 21420999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.
    Brown JW; Rueter LE; Zhang M
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():53-62. PubMed ID: 24269664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Executive function in schizophrenia: what impact do antipsychotics have?
    O'Grada C; Dinan T
    Hum Psychopharmacol; 2007 Aug; 22(6):397-406. PubMed ID: 17579928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Learning potential and cognitive remediation in schizophrenia].
    Raffard S; Gely-Nargeot MC; Capdevielle D; Bayard S; Boulenger JP
    Encephale; 2009 Sep; 35(4):353-60. PubMed ID: 19748372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm.
    Abdul-Monim Z; Reynolds GP; Neill JC
    Behav Brain Res; 2006 May; 169(2):263-73. PubMed ID: 16500717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive effects of conventional and atypical antipsychotics in schizophrenia.
    Sharma T
    Br J Psychiatry Suppl; 1999; (38):44-51. PubMed ID: 10884899
    [No Abstract]   [Full Text] [Related]  

  • 13. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
    Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
    Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cognitive deficits in schizophrenia and other psychotic disorders].
    Fagerlund B; Glenthøj BY
    Ugeskr Laeger; 2008 Nov; 170(46):3770-2. PubMed ID: 19014728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods for treating cognitive deficits in schizophrenia.
    Bowie CR; Jaga K
    Expert Rev Neurother; 2007 Mar; 7(3):281-7. PubMed ID: 17341176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic treatment in schizophrenia: the role of computerized neuropsychological assessment.
    Kertzman S; Reznik I; Grinspan H; Weizman A; Kotler M
    Isr J Psychiatry Relat Sci; 2008; 45(2):114-20. PubMed ID: 18982837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication.
    Snyder PJ; Jackson CE; Piskulic D; Olver J; Norman T; Maruff P
    Psychiatry Res; 2008 Sep; 160(3):316-26. PubMed ID: 18579217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Memory disorders in schizophrenia].
    Danion JM; Peretti S; Gras-Vincendon A; Singer L
    Encephale; 1992; 18 Spec No 2():315-28. PubMed ID: 1363948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.